Salvage locoregional therapies for recurrent hepatocellular carcinoma  

作　　者：Cody R Criss Mina S Makary 

机构地区：[1]Heritage College of Osteopathic Medicine,Ohio University,Athens,Ohio 45701,United States [2]Department of Radiology,The Ohio State University Wexner Medical Center,Columbus,Ohio 43210,United States

出　　处：《World Journal of Gastroenterology》2023年第3期413-424,共12页世界胃肠病学杂志（英文版）

摘　　要：Hepatocellular carcinoma(HCC)is the second most common cause of cancerrelated death worldwide.Despite the advent of screening efforts and algorithms to stratify patients into appropriate treatment strategies,recurrence rates remain high.In contrast to first-line treatment for HCC,which relies on several factors,including clinical staging,tumor burden,and liver function,there is no consensus or general treatment recommendations for recurrent HCC(R-HCC).Locoregional therapies include a spectrum of minimally invasive liver-directed treatments which can be used as either curative or neoadjuvant therapy for HCC.Herein,we provide a comprehensive review of recent evidence using salvage loco-regional therapies for R-HCC after failed curative-intent.

关 键 词：Recurrent hepatocellular carcinoma Locoregional therapy Transarterial chemoembolization Transarterial embolization Transarterial radioembolization Ablation Salvage therapy 

分 类 号：R735.7[医药卫生—肿瘤]